AI Drugs, Autophagy & Blue Zones Return | Longevity News Roundup — Week 2, 2026

In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick unpack the biggest stories shaping the longevity ecosystem from validated lifestyle science and AI-driven drug discovery to breakthrough clinical trials, CES health tech, and the future of longevity investing.A new study in the International Journal of Epidemiology confirms that Blue Zone populations still enjoy statistically significant longevity advantages, highlighting the role of community, movement, and diet in healthy aging.Insilico Medicine made headlines with its Hong Kong IPO, raising $293M and signaling strong investor confidence in AI-driven longevity biotech. The company also secured an $888M oncology collaboration with Servier, marking a major step for AI-powered drug discovery.At CES, Withings unveiled its at-home Longevity Station, a device that measures 60 biomarkers in just 90 seconds. It tracks cardiovascular function, vascular health, cellular composition, and early cardiometabolic risk, bringing advanced health monitoring into the home.Retro Biosciences dosed the first patient in a phase one trial of its autophagy-targeting drug, RTR242, a key milestone for clinical-stage longevity therapeutics.Human clinical evidence from El Nutra’s ProLon fasting-mimicking diet demonstrates measurable activation of autophagy, supporting cellular renewal, improved insulin sensitivity, and metabolic health.----------News & References:Insilico debuts on HK stock exchange, locking in more than $290M → https://longevity.technology/news/insilico-debuts-on-hk-stock-exchange-locking-in-more-than-290m/Insilico Medicine and Servier agree up to US$888M oncology collaboration → https://longevity.technology/news/insilico-medicine-and-servier-agree-up-to-us888-m-oncology-drug-discovery-collaboration/Retro Bio commences first-in-human trial for RIP242 → https://longevity.technology/news/retro-bio-commences-first-in-human-trial/Why long-bio is poised for a breakout at JPM 2026 → https://longevity.technology/news/why-longbio-is-poised-for-a-breakout-at-jpm-2026/Withings launches at-home Longevity Station at CES → https://longevity.technology/news/withings-launches-at-home-longevity-station-at-ces/First human trial links fasting-mimicking diet to cellular renewal → https://longevity.technology/news/first-human-trial-links-fasting-mimicking-diet-to-cellular-renewal/New study reaffirms Blue Zones longevity claims → https://longevity.technology/news/new-study-reaffirms-blue-zones-longevity-claims/----------Connect with our hosts:Phil Newman: https://qrco.de/bgXpNYDr. Nina Patrick: https://qrco.de/bgXpKn